1BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[ J]. N Engl J Med, 2000, 343(21 ) :1520 - 1528.
2SCHNITZER TJ, BURMESTER GR, MYSLER E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial[ J]. Lancet, 2004, 364(9435 ) :665 - 674.
3SILVERSTEIN FE, FAICH G, GOLDSTEIN JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS stud- y: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[ J]. JAMA, 2000, 284 (10) : 1247 - 1255.
4LAINE L, CURTIS SP, CRYER B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [ J ]. Lancet, 2007, 369 (9560) :465 - 473.
5BRESALIER RS, SANDLER RS, QUAN H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma che- moprevention trial[ J ]. N Engl J Med, 2005, 352 (11 ) :1092 - 1102.
6BERTAGNOLLI MM, EAGLE C J, ZAUBER AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas [ J ]. N Engl J Med, 2006, 355 ( 9 ) :873 - 884.
7KEARNEY PM, BAIGENT C, GODWIN J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials [ J]. BMJ, 2006, 332 (7553) : 1302 - 1308.
8MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296(13): 1633 -1644.
9HINZ B, RENNER B, BRUNE K. Drug insight: cyclo-oxygenase-2 inhibitors a critical appraisal [ J ]. Nat Clin Pract Rheumatol, 2007, 3 (10) :552 - 560.
10ZANCHETTI A, HANSSON L, DAHLOF B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group[ J]. J Hypertens, 2001, 19 (6) :1149 - 1159.
